Allspring Global Investments Holdings LLC Sells 9,916 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Allspring Global Investments Holdings LLC decreased its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 16.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 51,616 shares of the company’s stock after selling 9,916 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Kiniksa Pharmaceuticals were worth $905,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Tejara Capital Ltd grew its position in Kiniksa Pharmaceuticals by 3.2% in the third quarter. Tejara Capital Ltd now owns 35,000 shares of the company’s stock valued at $608,000 after acquiring an additional 1,069 shares during the last quarter. Profund Advisors LLC boosted its stake in shares of Kiniksa Pharmaceuticals by 7.8% in the 3rd quarter. Profund Advisors LLC now owns 23,506 shares of the company’s stock valued at $408,000 after purchasing an additional 1,700 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Kiniksa Pharmaceuticals by 2.5% in the 3rd quarter. Deutsche Bank AG now owns 91,726 shares of the company’s stock valued at $1,593,000 after purchasing an additional 2,220 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Kiniksa Pharmaceuticals by 349.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,097 shares of the company’s stock valued at $72,000 after purchasing an additional 3,186 shares during the last quarter. Finally, IFP Advisors Inc acquired a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $65,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Trading Up 3.4 %

Shares of KNSA stock opened at $17.68 on Wednesday. The business’s 50-day moving average price is $19.36 and its 200-day moving average price is $18.00. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $10.65 and a 12 month high of $22.09. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of 98.23 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Wednesday, February 28th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.15. Kiniksa Pharmaceuticals had a net margin of 5.11% and a negative return on equity of 6.12%. The business had revenue of $83.40 million for the quarter, compared to the consensus estimate of $72.31 million. On average, sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO Michael R. Megna sold 5,126 shares of the firm’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total transaction of $111,695.54. Following the completion of the transaction, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at approximately $383,242.52. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Sanj K. Patel sold 5,582 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $21.00, for a total value of $117,222.00. Following the sale, the chief executive officer now directly owns 65,012 shares in the company, valued at $1,365,252. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Michael R. Megna sold 5,126 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total transaction of $111,695.54. Following the sale, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at approximately $383,242.52. The disclosure for this sale can be found here. Insiders have sold a total of 33,109 shares of company stock valued at $709,929 over the last 90 days. 54.23% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Wedbush restated an “outperform” rating and issued a $30.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Tuesday. TheStreet upgraded Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Thursday, February 29th.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.